News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,466 Results
Type
Article (40325)
Company Profile (304)
Press Release (656837)
Section
Business (205604)
Career Advice (2361)
Deals (35654)
Drug Delivery (89)
Drug Development (81564)
Employer Resources (170)
FDA (16267)
Job Trends (14911)
News (347912)
Policy (32909)
Tag
Academia (2592)
Alliances (49763)
Alzheimer's disease (1297)
Approvals (16226)
Artificial intelligence (162)
Bankruptcy (355)
Best Places to Work (11668)
Biotechnology (211)
Breast cancer (202)
Cancer (1491)
Cardiovascular disease (119)
Career advice (1935)
Cell therapy (307)
Clinical research (65406)
Collaboration (554)
Compensation (302)
COVID-19 (2573)
C-suite (129)
Data (1468)
Diabetes (185)
Diagnostics (6290)
Earnings (85439)
Employer resources (148)
Events (111673)
Executive appointments (462)
FDA (17025)
Funding (501)
Gene therapy (219)
GLP-1 (620)
Government (4469)
Healthcare (19023)
Infectious disease (2669)
Inflammatory bowel disease (113)
Interviews (397)
IPO (16512)
Job creations (3657)
Job search strategy (1664)
Layoffs (425)
Legal (7948)
Lung cancer (220)
Manufacturing (214)
Medical device (13397)
Medtech (13402)
Mergers & acquisitions (19382)
Metabolic disorders (488)
Neuroscience (1653)
NextGen: Class of 2025 (6609)
Non-profit (4520)
Northern California (1853)
Obesity (278)
Opinion (186)
Parkinson's disease (106)
Patents (130)
People (57138)
Phase I (20365)
Phase II (28826)
Phase III (21425)
Pipeline (605)
Postmarket research (2583)
Preclinical (8651)
Radiopharmaceuticals (239)
Rare diseases (282)
Real estate (5943)
Regulatory (22017)
Research institute (2355)
Resumes & cover letters (408)
Southern California (1595)
Startups (3608)
United States (16444)
Vaccines (574)
Weight loss (192)
Date
Today (125)
Last 7 days (882)
Last 30 days (2141)
Last 365 days (35325)
2025 (1347)
2024 (35531)
2023 (40437)
2022 (51587)
2021 (56153)
2020 (54536)
2019 (47174)
2018 (35495)
2017 (32562)
2016 (31900)
2015 (38005)
2014 (31704)
2013 (26756)
2012 (29001)
2011 (29766)
2010 (27698)
Location
Africa (760)
Arizona (203)
Asia (37921)
Australia (6292)
California (4191)
Canada (1534)
China (353)
Colorado (188)
Connecticut (199)
Europe (83065)
Florida (589)
Georgia (141)
Illinois (415)
Indiana (238)
Maryland (679)
Massachusetts (3246)
Michigan (181)
Minnesota (313)
New Jersey (1175)
New York (1193)
North Carolina (782)
Northern California (1853)
Ohio (151)
Pennsylvania (986)
South America (1142)
Southern California (1595)
Texas (600)
Utah (119)
Washington State (434)
697,466 Results for "gel e inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
May 29, 2024
·
3 min read
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to Progena
Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product (“revyve™”) to ProgenaCare Global LLC (“ProgenaCare”).
June 27, 2024
·
4 min read
FDA
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
October 7, 2024
·
5 min read
Biotech Bay
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
XOMA Corporation announced it has acquired an economic interest in three women’s health assets - XACIATO™ vaginal gel 2%, Ovaprene®, and Sildenafil Cream, 3.6% - from Daré Bioscience, Inc., for an upfront payment of $22 million.
April 30, 2024
·
7 min read
Press Releases
Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology
December 19, 2024
·
4 min read
Press Releases
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
November 28, 2024
·
5 min read
Pharm Country
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery Annual Meeting in Boston, MA on April 5-8, 2024.
April 2, 2024
·
4 min read
Business
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies, Ltd. today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 20, 2024
·
13 min read
Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel SprayKane will introduce its unique spray gel at the Boswick Burn and Wound Care Symposium
Kane Biotech Inc. announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium.
January 31, 2024
·
3 min read
Press Releases
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%
October 25, 2024
·
5 min read
1 of 69,747
Next
